



## **IEEE Transactions on Molecular, Biological, and Multi-scale Communications**

*Special Issue on “Molecular Communications for Diagnostics and Therapeutic Development of Infectious Diseases”*

### **Call for Papers**

Infectious diseases have affected humans for centuries and continue to pose as one major challenge for healthcare going forward. The recent viral COVID-19 infectious disease has transformed our lives dramatically. Besides a large number of deaths, the virus can also affect the health of the general population. Recent historical events have proven that various types of coronaviruses can have a tremendous impact, and examples of these include the Severe Acute Respiratory Syndrome (SARS) and the Middle East Respiratory Syndrome (MERS), which also showed a high mortality rate. Besides coronaviruses, there are numerous types of infectious diseases that continue to affect people. A number of diseases that have been around for centuries do not currently have cures, one notable example being HIV. The consequence of the spreading of these infectious diseases, which sometimes can evolve into pandemics, can and will affect the global economy. Besides traditional fields such as immunology and virology, novel multi-disciplinary approaches will be required to tackle infectious diseases with much needed diverse and innovative points of view.

This special issue will focus on developing molecular communication abstractions, models, simulation, and experiments for diagnosing and treating infectious diseases. This may include characterizing the infection process and the propagation behavior of the virus, all the way to new mechanisms for developing therapeutic treatments using communication and information theory as tools. Prospective authors are cordially invited to submit their original manuscript on topics including but not limited to:

- Molecular Communications modeling of infectious disease propagation
  - o Bacteria
  - o Fungi

- Parasites
- Viruses
  - Coronavirus (e.g., SARS-CoV-1, SARS-CoV-2, MERS-CoV)
  - Filovirus (e.g., Ebola)
  - Flavivirus (e.g. Dengue, Zika)
- Modeling Molecular Communication Systems of innate and adaptive immune response for infectious diseases
- Propagation models of infectious, transmissible, and communicable diseases
  - Modeling the airborne or mosquito-borne propagation or interspecies transmission of viruses
  - Modeling the propagation of antimicrobial drug resistance
- Molecular Communication Treatment techniques for infectious diseases
- Using phenotypic data for enhancing Molecular Communication Models for the development of therapeutic agents
- Microfluidic Molecular Communication Analysis techniques for infectious disease
- Using Molecular Communication binding models for designing therapeutic vaccines
- Use of nano-biology/medicine/technology and novel materials, which utilize Molecular Communication, to improve infectious disease diagnostics
- Molecular Communication simulation and modeling platforms for infectious diseases.
- Experimental platforms such as multi-organ-on-chips to speed up drug discovery using molecular communication and data analytics

### **Important Dates**

**Manuscript Submission Deadline:** 15<sup>th</sup> July 2020

**First Notification:** 15<sup>th</sup> September 2020

**Acceptance Notification:** 1<sup>st</sup> December 2020

**Final Manuscript Due:** 15<sup>th</sup> December 2020

**Publication Date:** First Quarter 2021

### **Guest Editors**

#### **Sasitharan Balasubramaniam**

Telecommunication Software & Systems Group

Waterford Institute of Technology

Waterford, Ireland

Email: [sasib@tssg.org](mailto:sasib@tssg.org)

#### **Massimilian Pierobon**

Department of Computer Science and Engineering

University of Nebraska-Lincoln

Nebraska, USA

Email: [maxp@unl.edu](mailto:maxp@unl.edu)

#### **Ilangko Balasingham**

Department of Electronic Systems

Norwegian University of Science and Technology

Trondheim, Norway &

Intervention Center

Oslo University Hospital  
Oslo, Norway  
Email: [ilangko.balasingham@ntnu.no](mailto:ilangko.balasingham@ntnu.no)

**Seppo Vainio**

Faculty of Biochemistry and Molecular Medicine  
University of Oulu  
Infotech Oulu,  
Borealis Biobank of Northern Finland, Oulu University Hospital  
Oulu, Finland  
Email: [seppo.vainio@oulu.fi](mailto:seppo.vainio@oulu.fi)

**Masamitsu Kanada**

Institute for Quantitative Health Science and Engineering  
Michigan State University  
Michigan, USA  
Email: [kanadama@msu.edu](mailto:kanadama@msu.edu)

**Mladen Veletic**

The Intervention Centre  
Oslo University Hospital  
Oslo, Norway  
Email: [mlavel@rr-research.no](mailto:mlavel@rr-research.no)

**Michael T. Barros**

BiomedTech  
Tampere University  
Tampere, Finland  
Email: [michael.barros@tuni.fi](mailto:michael.barros@tuni.fi)

**News**

T-MBMC is accepted for inclusion in SCOPUS and it is ranked within the top 7% journals in the computer networks and communications category

For further information about T-MBMC, see <http://mbmc.info/> or contact [cbchae@yonsei.ac.kr](mailto:cbchae@yonsei.ac.kr)

